Methods for reducing the incidence of necrotizing enterocolitis
AssigneeAbbott Laboratories
InventorsSusan E. Carlson, Debra L. Ponder, Michael B. Montalto, Margaret H. Dohnalek, John D. Benson, David A. Borror, David V. Diodato
Life of this patent
Estimating the term…
Abstract
Enteral formulas that contain long-chain polyunsaturated fatty acids (PUFAs), e.g., arachidonic acid (AA), and docosahexaenoic acid (DHA), essentially free of cholesterol, are described for use in methods for reducing the incidence of necrotizing enterocolitis. Compositions from egg yolk lipids are preferred as they contain ω-6 and ω-3 long chain PUFAs and are predominantly in a phosphtidylcholine form. This is believed to provide a synergetic effect.
Claims27
A method for reducing the incidence of necrotizing enterocolitis in an infant, said method comprising administering to an infant which is susceptible to necrotizing enterocolitis an effective amount of a composition comprising protein, carbohydrate and lipid, including at least 1.0 mg of ω-6 polyunsaturated fatty acids per kg per day.
The method according to claim, 9 wherein said administration is performed by feeding a sufficient amount of an enteral composition containing arachidonic acid and docosahexaenoic acid to deliver to said infant about 1.0 to about 60 mg per kg per day of arachidonic acid and about 0.25 to about 35 mg per kg per day of docosahexaenoic acid.
A method for providing nutrition to an infant susceptible to or having necrotizing enterocolitis, said method comprising enterally administering to said infant an effective amount of at least one ω-6 polyunsaturated fatty acid in a nutritional matrix comprising protein, carbohydrate and fats, said matrix providing at least 1.0 mg of ω-6 polyunsaturated fatty acids per kg per day.
Dependencies are inferred from the claim text.